JPRN-UMIN000006020已完成2 期
Phase II study of EC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Early Breast Cancer - Phase II study of EC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Early Breast Cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •past medical history of drug allergy HER2 positive breast cancer (IHC 3+, IHC 2+ and FISH +) Active double cancer Severe complications Symptomatic brain metastasis Severe mental disorder History of blood transfusions within 2 weeks Sever bone marrow suppression, renal dysfunction, liver dysfunction Body cavity fluid watery diarrhea on registration Active infection or potentiality infection allergic reaction of the nab-paclitaxel, paclitaxel or albumin During pregnancy or lactation Judged by the investigator to be unfit to be enrolled into the study
研究者
相似试验
招募中
2 期
Phase II study of EC followed by Nab-paclitaxel as neoadjuvant chemotherapy for HER2 negative with lymph node metastasesbreast cancerJPRN-UMIN000010685Saitama Medical Center,Saitama Medical University40
已完成
2 期
PhaseII study of Nab-paclitaxel followed by EC as neoadjuvant chemotherapy for the operable breast cancerBreast cancerJPRN-UMIN000022931Rakuwakai Otowa Hospital Breast oncology department24
招募中
2 期
A Phase II trial of nab-paclitaxel followed by EC as neoadjuvant chemotherapy for resectable breast cancer.breast cancerJPRN-UMIN000017382Tokyo Women's Medical University,Department of endocrine surgery36
已完成
2 期
Phase II study of Nab-paclitaxel followed by FEC as neoadjuvant chemotherapy for the operable breast cancerbreast cancerJPRN-UMIN000011048Kitasato University Kitasato Institute Hospital20
招募中
2 期
Phase II study of FEC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Primary Breast Cancerbreast cancerJPRN-UMIN000006428Toho University Omori Medical Center40